M
Michael K. Lichtman
Researcher at Boston University
Publications - 10
Citations - 1034
Michael K. Lichtman is an academic researcher from Boston University. The author has contributed to research in topics: Ustekinumab & Transforming growth factor. The author has an hindex of 6, co-authored 10 publications receiving 831 citations. Previous affiliations of Michael K. Lichtman include National Institutes of Health & Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells
Christopher A. Klebanoff,Steven E. Finkelstein,Deborah R. Surman,Michael K. Lichtman,Michael K. Lichtman,Luca Gattinoni,Marc R. Theoret,Navrose Grewal,Paul J. Spiess,Paul A. Antony,Douglas C. Palmer,Yutaka Tagaya,Steven A. Rosenberg,Thomas A. Waldmann,Nicholas P. Restifo +14 more
TL;DR: It is demonstrated that IL-15 can improve the in vivo antitumor activity of adoptively transferred CD8+ T cells, which provides several avenues for improving adoptive immunotherapy of cancer in patients.
Journal ArticleDOI
Transforming growth factor beta (TGF-β) isoforms in wound healing and fibrosis.
TL;DR: TGF‐β3 may offer a scar‐reducing therapy for acute and chronic wounds and fibrosing disorders.
Journal ArticleDOI
Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas.
A. Gehad,Michael K. Lichtman,Chrysalyne D. Schmults,Jessica E. Teague,Adam Calarese,Ying Jiang,Rei Watanabe,Rachael A. Clark +7 more
TL;DR: It is shown that MDSC are critical producers of NO in SCC and that NO inhibition restores vascular E-selectin expression, potentially enhancing T cell recruitment, and that iNOS inhibitors and other therapies that reduce NO production may be effective in the treatment of SCC.
Journal ArticleDOI
Ustekinumab for treatment of cutaneous Crohn's disease.
TL;DR: A patient with cutaneous CD affecting the vulva and perianal skin, which, at seven months, had a marked response to ustekinumab administered at higher doses than typically used for psoriasis, is presented.
Journal ArticleDOI
Common Cutaneous Parasites
TL;DR: This review will focus on the biology, clinical presentation, and treatment of the more common skin parasites that providers may encounter in the clinic: scabies, bedbugs, lice, and fleas.